Skip to main content
Equibles
BVS logo

BVS · Bioventus Inc. · Metrics

Track BVS — free

Use BVS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$13.63 -0.20 (-1.45%)
Russell 2000 member Rebalance outlook locked
Market Cap
$1.16B
Shares
84.09M

BVS metrics

87 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$13.83
Market cap
$1.16B

Price action

20 metrics
Price change (1W)
+1.7%
Price change (30D)
+0.8%
Price change (3M)
+55.6%
Price change (6M)
+67.3%
Price change (YTD)
+89.1%
Price change (1Y)
+98.2%
Trailing year
Price change (5Y)
-6.3%
52-week high
$15.26
52-week low
$6.51
Change from 52-week high
-7.8%
Change from 52-week low
+116.1%
Annualized volatility
51.0%
Annualized volatility (3M)
57.8%
Beta
0.6
RSI (14D)
55.5
Price vs SMA 50
+9.3%
Price vs SMA 200
+45.0%
Avg volume (3M)
707,008
Relative volume
0.7
Average dollar volume
$8.65M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
84.09M

Valuation

12 metrics
P / E (TTM)
18.3
Trailing earnings · reciprocal yield 5.5%
PEG ratio
0.1
EV / revenue
2.4×
reciprocal yield 42.2%
EV / EBITDA
13.2×
reciprocal yield 7.6%
EV / EBIT
23.7×
reciprocal yield 4.2%
P / sales
2.0×
reciprocal yield 50.1%
P / book
5.1
reciprocal yield 19.7%
FCF yield
8.1%
TTM · current market cap
Buyback yield
—
P / FCF
12.3
reciprocal yield 8.1%
P / operating cash flow
12.0
reciprocal yield 8.3%
Earnings yield
4.7%

Historical valuation

8 metrics
P / E historical average (3Y)
72.8×
reciprocal yield 1.4%
P / E historical average (5Y)
72.8×
reciprocal yield 1.4%
EV / revenue historical average (3Y)
1.8×
reciprocal yield 56.8%
EV / revenue historical average (5Y)
1.7×
reciprocal yield 57.5%
EV / EBIT historical average (3Y)
26.3×
reciprocal yield 3.8%
EV / EBIT historical average (5Y)
38.9×
reciprocal yield 2.6%
EV / EBITDA historical average (3Y)
21.5×
reciprocal yield 4.7%
EV / EBITDA historical average (5Y)
28.1×
reciprocal yield 3.6%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
68.7%
Operating margin
10.0%
Trailing 12 months
Net margin
9.4%
Gross profit (TTM)
$399.45M
Operating profit (TTM)
$58.28M
Net income (TTM)
$54.46M
Trailing 12 months
Diluted EPS (TTM)
$0.77
FCF margin
16.2%
Effective tax rate
-59.1%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
+3.8%
Year over year
Net income growth YoY
+348.3%
Revenue (TTM)
$581.85M
Trailing 12 months
EPS growth YoY
+327.3%
Shares change YoY
+3.4%
Year over year · more shares
Revenue CAGR (3Y)
+3.5%
Revenue CAGR (5Y)
+12.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
+5.5%

Quality

14 metrics
Return on equity
23.9%
Return on assets
8.1%
Debt / equity
1.1
Current ratio
1.7
EBITDA (TTM)
$104.23M
Free cash flow (TTM)
$94.29M
Quick ratio
1.2
Interest coverage
—
Net debt / EBITDA
2.1
Return on invested capital
—
Trailing 12 months
Net cash
−$219.00M
Latest balance sheet
Cash & equivalents
$29.46M
Total assets
$673.35M
Total debt
$248.45M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$96.87M
Capital expenditures (TTM)
$2.59M
R&D (TTM)
$11.57M
SG&A (TTM)
$322.48M
Stock compensation (TTM)
$14.92M
R&D / revenue
2.0%
Stock compensation / revenue
2.6%

Ownership (13F)

3 metrics
13F filers
157
13F filer change QoQ
0
Institutional ownership
64.3%

Short interest

3 metrics
Short interest
2.8%
Latest settlement · 2.3 days to cover
Days to cover
2.3d
Short-squeeze score
48 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1665988 CUSIP 09075A108 13F (30d) 103 filings 102 filers Visit website Investor relations